Table 2.
| Trial(s) from which data were sourced | DUAL II (Buse et al. 2014 [15]) | LIRA-ADD2BASAL (Ahmann et al. 2015 [18]) | BEGIN BB (Garber et al. 2012 [19]) | BEGIN Flex (Meneghini et al. 2013 [20]) and BOOST Intensify Basal (data on file, Novo Nordisk [21]) | Supplementary analysis: BEGIN BB (Garber et al. 2012 [19]) |
|---|---|---|---|---|---|
| Arm used | IDegLira ( N = 199) | Liraglutide 1.8 mg added to basal insulin (insulin glargine/insulin detemir) ( N = 225) | Basal–bolus (insulin glargine + insulin aspart) ( N = 56) ab | Up-titrated insulin glargine ( N = 329) b | Basal–bolus (insulin glargine or insulin degludec + insulin aspart) ( N = 210) b |
| Sex (male) (%) | 56.3 | 53.3 | 57.1 | 52.3 | 50.0 |
| Age (years) | 56.8 (8.9) | 59.3 (9.2) | 57.7 (10.9) | 58.3 (9.4) | 59.5 (9.3) |
| Body weight (kg) | 95.4 (19.4) | 90.2 (20.0) | 93.4 (16.0) | 83.3 (18.3) | 92.7 (17.8) |
| BMI (kg/m2) | 33.6 (5.7) | 32.3 (5.6) | 32.4 (4.5) | 30.0 (5.0) | 32.7 (4.7) |
| Disease duration (years) | 10.3 (6.0) | 12.1 (7.1) | 12.3 (6.5) | 11.9 (7.2) | 12.70 (6.36) |
| HbA1c (%) | 8.7 (0.7) | 8.2 (0.8) | 8.5 (0.9) | 8.4 (0.9) | 8.4 (0.8) |
| HbA1c (mmol/mol)c | 72.1 (8.1) | 66.2 (8.8) | 69.1 (9.9) | 67.9 (10.0) | 67.9 (9.2) |
| Race (caucasian/other) (%) | 78.9/21.1 | 76.4/23.6 | 80.4/19.6 | 64.4/35.6 | 78.1/21.9 |
Results are mean (SD) values, except for sex and race
BMI body mass index, HbA 1c glycated hemoglobin, IAsp insulin aspart, IDegLira insulin degludec/liraglutide, IGlar insulin glargine, SD standard deviation
aData are from the subgroup of non-insulin-naïve patients who were treated with IGlar + 3 × IAsp
bObserved results for basal–bolus (BB) and basal-only arms are on subsets of patients from the original trials (non-insulin-naïve patients) and therefore values cannot be found in the trial publications
cCalculated values